Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire John Paulson Standing Pat With His Top Small-Cap Picks

Page 1 of 2

At Insider Monkey we have been touting the advantages of investing in the top small-cap picks of prominent hedge funds since our inception. In this regard, today we decided to take a closer look at billionaire John Paulson‘s stock picks in the small-cap category, according to his fund Paulson & Co‘s latest 13F filing for the reporting period of March 31. These holdings largely remained unchanged over the quarter and included Extended Stay America Inc (NYSE:STAY), Houghton Mifflin Harcourt Co (NASDAQ:HMHC), Grifols SA, Barcelona (NASDAQ:GRFS), and Cobalt International Energy, Inc. (NYSE:CIE).


Paulson set up his own fund in 1994 with the objective of pursuing a merger arbitrage strategy. The money manager didn’t get into the spotlight until his bets against subprime mortgages, the toxic financial derivatives at the heart of the 2008 financial crisis. He also made another $5 billion in 2010 by betting on gold. The market value of Paulson & Co’s public equity portfolio stood at $19.64 billion at the end of the first quarter, with the healthcare sector accounting for 42% of the value of those holdings.

Paulson & Co is a fund that we have been following for the last couple of years along with over 700 other investment firms. We follow hedge funds because our research has shown that their stock picks historically managed to generate alpha even though the filings are up to 45 days delayed. We used a 60-day delay in our back tests to be on the safe side and our research showed that the 15 most popular small-cap stocks among hedge funds outperformed the S&P 500 Total Return Index by an average of 95 basis points per month between 1999 and 2012. After adjusting for risk, our calculations revealed that these stocks’ monthly alpha was 80 basis points. We have also been sharing and tracking the performance of these stocks since the end of August 2012, during which time they have returned 144%, outperforming the S&P 500 ETF by nearly 85 percentage points (see more details here).

Paulson held 47.66 million shares of Extended Stay America Inc (NYSE:STAY) valued at $930.83 million at the end of March. The stake represented 4.74% of the value of the fund’s public equity portfolio. Although down by nearly 8.6% over the past year, Extended Stay America Inc (NYSE:STAY)’s stock has appreciated by 2.85% year-to-date. The $4.06 billion owner and operator of 682 hotels delivered an EPS of $0.15 for the first quarter, which beat estimates by $0.01. Revenues of $287.6 million were also $1.9 million higher than expectations. The company has been undergoing a brand transformation phase, which included the renovation of hotels that hadn’t received that honour for at least ten years. Extended Stay America Inc (NYSE:STAY) now has a systematic renovation process in place whereby it is typically able to renovate its hotels over the course of three months for $1 million. A total of 39 hotels were renovated during the first quarter. According to Extended Stay America Inc (NYSE:STAY)’s CEO Jim Donald, a renovated hotel sees an eight point improvement in Revenue Per Available Room (RevPAR). Besides Paulson & Co, Mark T. Gallogly‘s Centerbridge Partners is the other leading stockholder of Extended Stay America Inc (NYSE:STAY), owning an identical stake of 47.66 million shares valued at $930.83 million.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!